Antibody-Drug Conjugates: Next-Generation Linker Technology For IND Submissions

The journey from discovery to investigational new drug (IND) application is fraught with complexity for bioconjugates. Linker design is a critical but often underestimated factor impacting development speed, ease, and final product quality. Hear from experts in this presentation and review key factors for successfully designing and developing bioconjugates as well as insights on how linker technologies can accelerate the journey to IND submission.

One of the highlights of the session will be an in-depth discussion on Abzena's innovative ThioBridge conjugation technology, exploring how this cutting-edge technology can revolutionize the field by enhancing the stability and efficacy of ADCs.

This webinar presents case studies to explore the complexities of oligonucleotide design, GMP standards for antibody-drug conjugates (ADCs), and how developability can play a significant role in selecting ADC leads with high potential. Don't miss this opportunity to streamline your bioconjugate development process and advance your candidates to the next stage efficiently.